Osiris Therapeutics (OSIR) Posts Q2 Loss of 11c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Join SI Premium – FREE
Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.29 million versus the consensus estimate of $4.35 million.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank's top picks in mining as copper market faces potential squeeze
- Parabolic reports preliminary Q3 2026 revenue of $4.7 million
- Yorkville Ives Starts Alphabet (GOOGL) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
